secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001493152-24-018020
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 3.02, 3.03, 5.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics closes $11.6M Series B-1 preferred offering; appoints Dennis Matheis to board
--------------------------------------------------------------------------------

- Gross proceeds from combined Series B / B-1 offering total $29.8M; $11.6M from Series B-1, $18.6M from prior Series B.
- Series B-1 convertible at $0.7228/share after 6-month anniversary; dividends in stock on first and second anniversary.
- Dennis Matheis, President/CEO of Sentara Health ($13B revenue), appointed Class A director effective May 6, 2024.
- Proceeds to extend working capital runway as company approaches critical reimbursement milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224018020/0001493152-24-018020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224018020/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer